Bing

SEARCH HISTORY

36Equity Research Institute has initiated coverage on the following equities: Isis Pharmaceuticals Inc. (NASDAQ: ISIS), Endo International PLC (NASDAQ: ENDP), Amarin Corporation PLC (NASDAQ: AMRN), United ... Inc.'s stock lost 2.48%, to close the …
New Jersey Online · 7/30/2015
The shares of AMRN are up 30.1% at an annual high of $2.54, after Wainwright & Co quadrupled its price target to $10, and upgraded the stock to "buy ... Today, the shares of Peabody Energy Corporation are down 4.5% to hit $5.85 -- and earlier touched ...
Schaeffer's Investment Research · 3/12/2015
New York, NY - (ACCESSWIRE) - 10/15/2013 - Equity Profile Report initiates its NASDAQ Active Stock Watch List adding Tesla Motors, Inc. (NASDAQ:TSLA), Ariad Pharmaceuticals Inc. (NASDAQ:ARIA), Coronado Biosciences, Inc. (NASDAQ:CNDO) …
4 Traders · 10/15/2013
The shares of Amarin Corporation plc (ADR) (NASDAQ:AMRN) fell as much as 17.68% after its announcement about the denial of its FDA rescission of the ANCHOR clinical trial Special Protocol Assessment (SPA) agreement. The Office of New Drugs …
stockwisedaily.com · 9/15/2014
Several oil and gas stocks under ... 8 and $9 stock the prior week. It seems hard to get excited here after such a big price drop this past week, but those calls were made that still implied high upside. On Thursday, Amarin Corp. PLC (NASDAQ: AMRN) was ...
24/7 Wall ST · 3/14/2015
Wall Street ratings agencies set the tone for today's stock market. Amarin (AMRN): Brokerage boutique H.C. Wainwright hoists the drug manufacturer to Buy from Neutral. American Tower REIT (AMT): ISI Group gives the diversified real estate investment …
Minyanville · ByJustin Sharon · 8/13/2013
In the report, Goldman Sachs noted, “Given that the upcoming advisory panel for AMRN's Vascepa in the expanded ANCHOR indication ... potential outcomes and what we think it could mean to the stock, as well as provide an options strategy.
Benzinga · ByDwight Einhorn · 10/9/2013
There won't be any retirement party, though. Amarin's ($AMRN) stock is down 80% over the past year, falling off a cliff two months ago when the biotech was handed a disastrous panel rejection on its application to sell Vascepa in combination with a statin ...
Fierce Biotech · ByJohn Carroll · 12/16/2013
The price of one share of stock, which is set by buyers and sellers in the market. Share price can be used to find a company's total market value, as represented by market capitalization. Prices of a stock will move throughout the day. Investors generally ...
YCharts · 7/22/2015
ELY CAMBRIDGESHIRE, UNITED KINGDOM (MMD Newswire) October 12, 2011 - - Fountain Healthcare Partners Ltd. exercised 2,500,000 shares of Amarin Corp Plc (AMRN) stock as noted in an SEC Filing today. Fountain Healthcare Partners Ltd.'s title …
MMD Newswire · 10/12/2011

Amarin Corporation

Company
Amarin Corporation is a biopharmaceutical company headquartered in Bedminster, New Jersey. The company develops and markets me…
Amarin Corporation is a biopharmaceutical company headquartered in Bedminster, New Jersey. The company develops and markets medicines for the treatment of cardiovascular disease. Amarin develops the drug Vascepa which is a prescription grade omega-3 fatty acid. In December 2007, the company acquired Ester Neurosciences Limited for 8.1 million USD. Amarin CEO Joe Zakrzewski has said that the company would like to first work on building its infrastructure out to commercialize the drug in the United States. Recently on July 26, 2012, their lead-candidate drug named Vascepa received FDA-approval. Vascepa will also be a key competitor against GlaxoSmithKline's Lovaza.
Data from: Wikipedia